Background. Clinical implications of persistent alanine aminotransferase (ALT) elevation and associated factors in chronic hepatitis C (CHC) patients who achieved undetectable hepatitis C virus (HCV) RNA during pegylated interferon plus ribavirin ( peg-IFN/RBV) therapy remain unknown.
acting antiviral agents (DAAs) have been approved for treatment of chronic HCV infection since 2011, combination therapy with pegylated interferon plus ribavirin ( peg-IFN/RBV) remains the standard of care for chronic HCV infection, with an overall sustained virological response (SVR) rate of 50%-76% in areas where DAAs are not available [2] [3] [4] [5] . Several viral and host factors, including the presence of rapid virological response (RVR), HCV genotype 2 or 3, lower pretreatment viral load, female sex, favorable interleukin 28B (IL28B) genotype, and mild hepatic fibrosis, are found to predict SVR to peg-IFN/RBV therapy [6, 7] .
Although on-treatment biochemical response plays a minor role in predicting SVR, a rapid decline of serum alanine aminotransferase (ALT) level and ALT normalization after therapy are favorable indicators of SVR [8, 9] . In most clinical conditions, reduction of ALT level is parallel with the decrease in HCV viremia and hepatic necroinflammation. However, fluctuating or even persistently elevated ALT level is frequently observed in patients on IFN-based therapy, even in those already negative for HCV RNA [10] [11] [12] [13] . Although virological response does not guarantee biochemical response, lack of ALT normalization may discourage patients with chronic hepatitis C (CHC) to complete the therapy with substantial side effects. Previous studies have suggested that higher body mass index (BMI) and hepatic steatosis were associated with ALT elevation during therapy [11, 13] . However, the mechanisms involved in persistent ALT elevation during therapy are largely unknown and deserve further study.
To this end, we assessed the prevalence of persistent ALT elevation in CHC patients who had HCV RNA clearance during peg-IFN/RBV therapy and explored its impact on posttreatment outcomes. We also compared the baseline characteristics between patients with and without persistent ALT elevation during therapy to identify factors associated with this specific phenomenon.
PATIENTS AND METHODS

Study Population
A total of 1238 treatment-naive patients with chronic HCV genotype 1 (HCV-1) and genotype 2 (HCV-2) receiving peg-IFN/RBV between 2005 and 2013 were enrolled [5, [14] [15] [16] . Chronic HCV infection was defined by the presence of anti-HCV antibody (Abbott HCV enzyme immunoassay 3.0, Abbott Laboratories) and serum HCV RNA by real-time reverse transcription polymerase chain reaction analysis (Cobas TaqMan HCV Test version 2.0, Roche Diagnostics GmbH; limit of detection: 15 IU/mL) for >6 months. Human genomic DNA was extracted from peripheral blood mononuclear cells by QIAamp kits (Qiagen). IL28B single-nucleotide polymorphism (rs8099917) genotypes (homozygous TT, heterozygous GT, and homozygous GG) were analyzed by ABI TaqMan allelic discrimination kit and the ABI7900HT Sequence Detection System (Applied Biosystems) [14, 15] . Patients were not enrolled if they had mixed infection with another genotype of HCV, coinfection with hepatitis B virus (HBV), chronic alcohol abuse (daily alcohol consumption >20 g/day), decompensated cirrhosis, neoplastic disease, and organ transplant.
Treatment Protocol
HCV-1 patients were treated with peg-IFN alfa-2a 180 µg/week (Pegasys, Hoffman-LaRoche) or peg-IFN alfa-2b 1.5 µg/kg/ week (Peg-Intron, Merck Sharp & Dohme) and RBV 1000-1200 mg/day (Copegus, Hoffman-LaRoche; 1000 mg/day for patients weighing <75 kg and 1200 mg/day for those weighing ≥75 kg) for 24 weeks or 48 weeks. HCV-1 patients treated with nonstandard 24-week therapy were from our previous clinical trials between 2006 and 2010 in Taiwan, in which patients were randomly assigned to receive 24 or 48 weeks of peg-IFN/RBV therapy [5, 14, 15] . Some HCV-1 patients undergoing 24 weeks of treatment were on the basis of response-guided therapy (ie, patients who achieved RVR were treated for 24 weeks). HCV-2 patients were treated with peg-IFN/RBV 800 mg/day for 24 weeks.
Pretreatment demographics, hemogram, serum fasting blood glucose, glycated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), aspartate aminotransferase (AST), and ALT levels were collected. BMI was calculated as weight in kilograms divided by height in square meters. The AST to platelet ratio index (APRI) was calculated as [(AST/upper limit of normal [ULN])/platelet count (10 9 /L)] × 100 [17, 18] . The ULN for AST and ALT was 40 IU/L. Each patient received baseline ultrasound-guided percutaneous liver biopsy. All biopsy specimens were evaluated by an experienced pathologist. The staging of hepatic fibrosis was scored using the Metavir system, ranging from F0 to F4 [19] . Advanced hepatic fibrosis was defined as a Metavir fibrosis stage of ≥F3. The classification of steatosis was according to the proportion of lipid-containing hepatocytes per high-power field (grade 0: <5%, grade 1: 5%-33%, grade 2: 33%-66%, grade 3: >66%) [20] . Serum HCV RNA level was evaluated at baseline, weeks 4 and 12 of treatment, at the end of treatment, and at week 24 posttreatment. RVR, complete early virological response (cEVR), and SVR were defined as undetectable serum HCV RNA at week 4 of treatment, at week 12 of treatment in the absence of RVR, and at week 24 posttreatment, respectively. Viral breakthrough was defined as serum HCV RNA being detectable during the treatment, but once undetectable at earlier treatment. Viral relapse was defined as serum HCV RNA being undetectable at the end of treatment but detectable at the end of follow-up.
Study Cohort
Serum ALT changes were evaluated in patients who achieved RVR or cEVR during treatment. Patients who had withdrawn from treatment, or who had poor virological response, virological breakthrough, unavailable HCV RNA data to determine virological responses, or loss to follow-up were excluded from the study. ALT level was measured monthly until 6 months after the end of the therapy. Persistent ALT elevation was defined as patients with on-treatment ALT level >1.5 times the ULN (ALT > 60 IU/L) for ≥3 months after achieving undetectable HCV RNA. By setting the cutoff ALT level of >1.5 times the ULN as persistent on-treatment ALT elevation (POAE), we then designated the pretreatment level as 2 times the ULN of POAE (ie, baseline cutoff ALT level of ≥3 times ULN) as the factor included for univariate and multivariate analyses to minimize potential confounding factors affecting ALT elevation.
Patients with persistent ALT elevation and those without persistent ALT elevation during treatment were classified as groups I and II, respectively. The baseline demographic (age, sex, BMI), clinical (ALT, metabolic features, APRI score, fibrosis stages, steatosis grade), and viral (HCV RNA, HCV genotype, IL28B genotype) characteristics, as well as the SVR rates, were compared between groups I and II.
Statistical Analyses
The data are presented as percentages for categorical variables and mean with standard deviations for continuous variables. Univariate analyses of pretreatment variables were performed by 2-sample t test and χ 2 test, with Fisher exact test when appropriate. Pretreatment variables with P values of ≤.05 by univariate analyses entered into multivariate logistic regression analysis to find independent factors, which were expressed as odds ratios (ORs) with 95% confidence intervals (CIs), to predict POAE after viral clearance. Statistical analyses were performed using Stata software (version 11.0; StataCorp). A P value < .05 was considered statistically significant and all statistical tests were 2-tailed.
RESULTS
Patient Characteristics
A total of 125 patients were excluded in this study. The baseline demographic, clinical, and viral characteristics of the remaining 1113 patients who were eligible for the study are shown in Abbreviations: ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; BMI, body mass index; HbA1c, glycated hemoglobin; HCV, hepatitis C virus; IL28B, interleukin 28B; peg-IFN, pegylated interferon; RVR, rapid virological response; SVR, sustained virological response; TC, total cholesterol; TG, triglyceride; ULN, upper limit of normal. a P < .05 when compared HCV-1 patients received 48 weeks of treatment to those received 24 weeks of treatment. b IL28B genotyping was available in 1102 patients.
baseline characteristics and virological responses in patients with or without POAE after viral clearance are shown in Table 2 . Patients with age ≥55 years (P = .009), BMI ≥ 27 kg/m 2 (P < .0001), ALT level ≥3 times the ULN (P < .0001), HbA1c ≥ 6.5% (P < .0001), TG ≥ 150 mg/dL (P < .0001), TC ≥ 200 mg/dL (P = .004), APRI score ≥ 1.5 (P < .0001), advanced hepatic fibrosis (P < .0001), and high-grade hepatic steatosis (P < .0001) were associated with POAE after viral clearance. In contrast, male sex (P = .942), baseline HCV RNA level (P = .238), HCV genotype (P = .936), IL28B genotype (P = .245), and types of peg-IFN treatment (P = .178) were comparable between group I and II patients. Patients with POAE had a lower SVR rate than patients without POAE after viral clearance (74.0% vs 85.2%, respectively; P < .0001; Table 4 ). In subgroup analysis, the SVR rates of patients with and without POAE were comparable for those who achieved RVR, regardless of HCV genotypes or treatment duration. In contrast, among HCV-1 patients who achieved cEVR and received 48 weeks of treatment, the SVR rate in patients with POAE was lower than in those without POAE (44.1% vs 74.0%, respectively; P = .0002).
Multivariate Analysis of Baseline Factors Associated With POAE After Viral Clearance
Analysis of Baseline Characteristics in Patients With or Without Persistent On-Treatment Alanine Aminotransferase Elevation After Viral Clearance
DISCUSSION
The successful treatment of chronic HCV infection assessed by virological, biochemical, and histological response has been shown to prevent or delay disease progression to cirrhosis and HCC [21] . A rapid normalization of ALT level together with viral clearance during peg-IFN/RBV therapy is a favorable sign of successful treatment. In contrast, POAE may be due to poor virological response and direct or indirect drug-related effects. However, the clinical implications of persistently elevated ALT elevation after viral clearance and associated factors remain largely unclear. Basso et al reported that approximately onethird of patients who were HCV RNA negative during peg-IFN/RBV therapy had ALT elevation, but no specific factors were identified to be associated with this phenomenon [12] . In this study, the prevalence of POAE after viral clearance was 22.8%. The discrepancy between these 2 studies may be attributed to different definitions of on-treatment ALT elevation. Basso et al defined elevated ALT levels to be greater than the ULN (>40 IU/L) for at least 1 of the programmed evaluations after undetectable HCV RNA, whereas in our study patients who experienced ALT level >1.5 times the ULN for at least 3 of the programmed evaluations after viral clearance were defined as having persistently elevated ALT. We intended to adopt the more strict definition to diminish the potential confounding factors associated with this phenomenon. Therefore, we could demonstrate that higher BMI, higher pretreatment ALT level, and higher APRI score as well as advanced liver fibrosis and steatosis were associated with POAE in patients without viremia. The mechanisms involved in POAE after HCV clearance remain elusive. The possible explanation is direct or indirect drug-induced hepatopathy. Although peg-IFN and RBV could inhibit viral replication, they may not regulate the production of proinflammatory cytokines or chemokines [22] . Furthermore, interferon had immunomodulatory effects, including cytokine production (interleukin 4, interleukin 6 [IL-6], interleukin 10, and tumor necrosis factor alpha [TNF-α]) and increased natural killer and cytotoxic T-cell activity [23] . These proinflammatory cytokines and chemokines act as mediators of necroinflammation within the liver. If this explanation holds true, the necroinflammation-related ALT elevation during interferon therapy will improve after cessation of treatment. Another possible explanation is a preexisting pathogenic condition, such as advanced liver fibrosis or hepatic steatosis. Aoki et al demonstrated the histologic findings of 2 patients who had continuously abnormal ALT levels despite undetectable HCV RNA [13] . Presence of hepatic steatosis, severe necroinflammation, and hepatocyte degeneration were observed in these patients. Our data Figure 1 . The virological and biochemical responses of 1113 patients during treatment, at the end of treatment, and at the end of follow-up. Abbreviations: ALT, alanine aminotransferase; cEVR, complete early virological response; EOT, end of treatment; HCV, hepatitis C virus; RVR, rapid virological response; SVR, sustained virological response. *Persistent ALT elevation was defined as ALT levels >1.5 times the upper limit of normal (ULN) for ≥3 months after viral clearance; abnormal ALT levels were defined as ALT levels greater than ULN.
lent support to their findings that high grade of hepatic steatosis, high pretreatment ALT level, and advanced hepatic fibrosis contributed to POAE after viral clearance [24] .
In multivariate analysis, we found that advanced hepatic fibrosis and high grade of steatosis were the strongest factors predictive of POAE after viral clearance. Although BMI ≥ 27 kg/m 2 and APRI score ≥ 1.5, which were highly correlated with hepatic steatosis and advanced hepatic fibrosis, were also independent predictors, their predictive values were less pronounced when the histologic data of steatosis and fibrosis were taken into consideration [25] . Nevertheless, applying these 2 simple noninvasive BMI and APRI indices can provide useful information about the risk of POAE for patients who were unwilling or ineligible to receive invasive liver biopsy.
The mechanism of liver damage caused by HCV is not yet fully understood, but could be attributed to either direct cytopathic or immune-mediated injury. Our study showed that a high baseline ALT level (≥3 times ULN) was significantly and independently associated with POAE after HCV clearance. Although the serum ALT level is considered to be a marker of histological damage, the correlation between serum ALT level and hepatic fibrosis is still controversial [26] . High ALT level is associated with a higher risk of liver fibrosis progression, whereas a baseline ALT level ≥3 times the ULN was also a predictor for better response to peg-IFN/RBV [5] . In addition to high rates of favorable IL28B genotype and HCV subtype 1b infection, a substantial proportion of patients (41.1%) with a baseline ALT level ≥3 times the ULN may contribute to the higher SVR rates in our patients. Although patients with POAE had higher rates of baseline ALT level ≥3 times the ULN than those without POAE (62.3% vs 34.6%), the overall SVR rate of patients with POAE was inferior to that of patients without POAE. It implied that advanced hepatic fibrosis and steatosis, which were highly associated with POAE and poor treatment responses, may outweigh the beneficial effects of high baseline ALT levels in our patients, particularly in HCV-1 patients who had cEVR and who received 48 weeks of treatment.
Hepatic steatosis is a common histological feature occurring in >50% of patients with CHC [27] . Both host and viral factors have been demonstrated to play an important role in the development of hepatic steatosis. Viral steatosis is mostly reported in patients with genotype 3, whereas metabolic steatosis is often associated with genotype 1 and metabolic syndrome. Hepatic steatosis is an important cofactor to enhance liver necroinflammatory activity in CHC [28] . In patients with CHC, obesity and steatosis may increase the expression of selected inflammatory cytokines, such as IL-6 and TNF-α [29] . In addition, in patients with advanced hepatic fibrosis or increased ALT level, soluble TNF receptor levels were significantly increased, indicating the activation of the TNF system [30] . Furthermore, HCV infection also induces insulin resistance. The insulin resistance was higher in CHC patients than healthy controls or patients of non-HCV-related liver disease with matched sex, BMI, and age [31] . The improvement of insulin resistance is observed in HCV-infected patients with treatment-inducted viral clearance, but this phenomenon is not observed in those with nonresponse or relapse to treatment [32] .
On the basis of 2-hit hypothesis, insulin resistance and oxidative stress play an important role in the pathogenesis of nonalcoholic steatohepatitis [33] [34] [35] . Previous studies indicated that patients with high grade of hepatic steatosis and advanced hepatic fibrosis were associated with insulin resistance, and the administration of peg-IFN, which may further increase the expression of inflammatory cytokines causing oxidative stress, triggered a second hit in such patients [36] . In this study, patients with higher BMI, higher grade of hepatic steatosis, and advanced hepatic fibrosis exhibited more POAE despite the absence of viremia. Because the treatment-induced cytokine surges might wane after the cessation of IFN-based therapy, we thus hypothesized that most of our patients with POAE who achieved SVR would have ALT normalization. The possible interplay of insulin resistance and the cytokine dynamics, and whether the use of insulin sensitizers or anti-TNF-α agents may ameliorate the POAE or even improve the treatment response deserve further study. Previous studies showed controversial results regarding the impact of on-treatment ALT elevation on the treatment response [10] [11] [12] [13] . Our data suggested that patients with POAE had a lower SVR rate than those without (74.2% vs 85.0%). Because hepatic steatosis, advanced fibrosis, and obesity are known negative predictors for SVR, it is plausible that under the same on-treatment viral kinetics, patients with POAE due to these negative factors may have a lower SVR rate than those without [37] . For example, compared with HCV-1 patients with RVR, the SVR rate is far from satisfactory in HCV-1 patients who failed to achieve RVR [38] . In our patients achieving RVR, the SVR rate was comparable, regardless of ontreatment ALT level. However, in HCV-1 patients who achieved cEVR, the SVR rate in patients with POAE was significantly lower than that in patients without POAE by 48 weeks of treatment (44.1% vs 74.0%). Because HCV-1 patents with cEVR can benefit from extended duration of combination therapy to 72 weeks if they remain viremic at week 8 of treatment, we speculated that patients who failed to achieve viral clearance at week 8 of treatment might have negative factors such as advanced hepatic fibrosis or steatosis [15, 39] . Therefore, these patients were also prone to have POAE despite viral clearance after week 12 of treatment. Taken together, healthcare providers should encourage patients with HCV-1 or HCV-2 who achieved RVR to continue treatment despite POAE, and may extend the treatment duration to 72 weeks or apply novel DAAs to HCV-1 patients who achieved cEVR and had POAE to improve the SVR rate.
Our study enrolled an Asian population with high rates of favorable IL28B genotype and HCV subtype 1b infection, and therefore they tend to have better interferon responsiveness than other ethnic populations [40] . Because these results might vary among different populations, further studies focusing on non-Asian populations are needed to confirm our findings.
Although combination therapy of peg-IFN/RBV remains the standard of care in many Asian countries where DAA has not yet been available, it is no longer recommended in Western countries. Nevertheless, our results may provide a predictive value in the all-oral DAA era of HCV therapy if these findings could be reproduced in future studies on HCV patients receiving all-oral DAA therapy. In fact, similar findings were reported in HBV patients with long-term tenofovir therapy [41] . In this study, high BMI and hepatic steatosis were associated with fibrosis progression in HBV patients who had a sustained viral response (undetectable HBV DNA). Therefore, even in the all-oral DAA era of HCV therapy, practicing physicians should pay close attention to patients who have POAE after achieving undetectable HCV RNA, because they are still at risk of disease progression and HCC development due to hepatic steatosis and advanced hepatic fibrosis. Lifestyle modification and HCC surveillance are required for this special clinical setting.
In conclusion, persistent ALT elevation during peg-IFN/RBV therapy is not uncommon, even in patients achieving undetectable HCV RNA. Viral clearance with ALT normalization during therapy can be recognized as a favorable treatment response, especially in HCV-1 patients with cEVR who received 48 weeks of combination therapy. Higher pretreatment ALT level, higher BMI, higher APRI score, higher grade of steatosis, and advanced fibrosis are predictors for POAE after viral clearance.
